The Oklahoma Shared Clinical and Translational Resources

The OSCTR is funded by the National Institutes of Health as part of its IDeA-CTR program. We have the mission to serve as a catalyst for clinical and translational research that improves health and healthcare for Oklahomans, to provide training and infrastructure to help junior investigators to launch independent research careers, and to expand the opportunities of IDeA states and Oklahoma communities to participate in research that improves the health of our residents. 

Oklahoma Clinical and Translational Science Institute

 

OCTSI is the home of the OSCTR, as well as clinical research services and dissemination and implementation resources to help improve the delivery of healthcare. 

Oklahoma Primary Healthcare Improvement Cooperative

 

OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.

OCTSI Clinical Research Unit

​​

The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.

​

 

 

 

 

 

University of Oklahoma Health Sciences Receives Federal Funding to Improve Health Care Access Across the State

Submitted by alex on

Across large areas of Oklahoma and the nation, primary care clinics are a lifeline, providing care for people who otherwise would have to travel many miles to see a doctor. To increase access to vital health care, the National Institutes of Health announced an ambitious new initiative to integrate NIH-funded clinical trials into routine patient care in areas like rural Oklahoma and within Tribal nations.

OU Awarded $17 Million NIH Grant to Improve Cancer Outcomes Among Native Americans

Submitted by Anonymous (not verified) on

The National Institutes of Health has awarded the University of Oklahoma a five-year, $17.2 million grant to partner with tribal nations and communities to improve cancer outcomes. Research has shown that the American Indian and Alaska Native population in Oklahoma experiences a 36% higher incidence of cancer and a 73% higher death rate from cancer than faced by the U.S. general population.

Subscribe to News

Recent Publications

Impact of Preexisting Rare Diseases on COVID-19 Severity, Reinfection, and Long COVID, and the Modifying Effects of Vaccination and Antiviral Therapy: A Retrospective Study from the N3C Data Enclave

medRxiv [Preprint]. 2025 Jul 10:2025.07.09.25331138. doi: 10.1101/2025.07.09.25331138.

ABSTRACT

BACKGROUND: Over 10,000 rare diseases (RDs) affect more than 300 million people globally, yet their influence on COVID-19 severity, reinfection risk, and long COVID remains poorly understood. This study evaluates the impact of RDs on these outcomes and examines the effectiveness of vaccination and antiviral treatments among individuals with and without RDs.

Use of flavored and modified risk smokeless tobacco products among American Indian adults

Nicotine Tob Res. 2025 Feb 26:ntaf047. doi: 10.1093/ntr/ntaf047. Online ahead of print.

ABSTRACT

INTRODUCTION: Little is known about the use of modified risk smokeless tobacco products (MRSTP) and flavored smokeless tobacco (ST) products among American Indians (AI). Aim of this study is to evaluate differences in tobacco use characteristics, ST dependence, and cotinine levels according to the use of flavored ST and MRSTP among AI ST users.

Media

Copyright © 2025 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer | Copyright | Equal Opportunity Employer

Built and Managed by the OCTSI. Base theme by Zymphonies